TCWP’s Ascendis Pharma A/S ASND Stock Holding History

TCWP’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6	Closed	–	–	370
2022 Q1	$0	Buy	+6	New	+$695	﹤0.01%	1721

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCWP's ASND Position: Q2 2022 in Review

TCWP sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 6 shares.

TCWP first reported a position in ASND in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

TCWP reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
TCWP sold 6 Ascendis Pharma A/S shares in Q2 2022.
TCWP first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 1 quarter.
TCWP's Ascendis Pharma A/S position peaked at $0 in Q1 2022.
168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.